ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021
A New Panel-Estimated GFR, Including β
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 72 citations in OpenAlex.
- Effect of Dapagliflozin on Measured vs. Panel-Estimated Glomerular Filtration Rate.Clinical pharmacology and therapeutics · 2025Trial
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.Nature medicine · 2024Trial
- Contrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunction.Science advances · 2026Article
- Impact of Computed Tomography-Derived Body Composition Analysis on the Performance of GFR Estimating Equations in Patients with Cancer.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Multi-Marker Evaluation of Creatinine, Cystatin C and β2-Microglobulin for GFR Estimation in Stage 3-4 CKD Using the 2021 CKD-EPI Equations.International journal of molecular sciences · 2026Article
- Study variation in estimating Glomerular Filtration Rate (GFR) from serum creatinine, cystatin C, age, and sex.PloS one · 2026Article
- Quantitative Analysis of a Novel Metabolite Panel to Estimate GFR (Panel eGFR) in Serum and Plasma Using LC-MS/MS.Clinical chemistry · 2025Article
- Complex Etiologies of the Discordance Between Cystatin C- and Creatinine-Based Estimated GFR and Its Adverse Associations: Findings From the CRIC Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Article
- Continuous beta-2 microglobulin-based clearance highlights superiority of high-Dose HDF over high-flux HD in predicting outcomes.Scientific reports · 2025Article
- Clinical Algorithms and the Legacy of Race-Based Correction: Historical Errors, Contemporary Revisions and Equity-Oriented Methodologies for Epidemiologists.Clinical epidemiology · 2025Review
- Evaluation of Race-Neutral Glomerular Filtration Rate Estimating Equations in an Indian Population.Kidney international reports · 2024Article
- CKD Prevalence and Incidence in Older Adults Using Estimated GFR With Different Filtration Markers: The Atherosclerosis Risk in Communities Study.Kidney medicine · 2024Article
- Comparison of Glomerular Filtration Rate Equations in a Rural New Mexico Cohort: Results from the COMPASS Study.medRxiv : the preprint server for health sciences · 2024Article
- Consistency of metabolite associations with measured glomerular filtration rate in children and adults.Clinical kidney journal · 2024Article
- Erratum regarding "A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population" (Am J Kidney Dis. 2021;77(5):673-683).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Article
- Proteogenomics in Nephrology: A New Frontier in Nephrological Research.Current issues in molecular biology · 2024Review
- Evaluation of novel candidate filtration markers from a global metabolomic discovery for glomerular filtration rate estimation.Kidney international · 2024Article
- Performance of GFR Estimating Equations in Young Adults.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Article
- Biomarkers of chronic kidney disease in older individuals: navigating complexity in diagnosis.Frontiers in medicine · 2024Review
- Role of Estimated Glomerular Filtration Rate in Clinical Research: The Never-Ending Matter.Reviews in cardiovascular medicine · 2024Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
18 authors at 14 institutions in 4 countries.
Lesley A InkerDivision of Nephrology, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA. Electronic address: linker@tuftsmedicalcenter.org.
Sara J CoutureDivision of Nephrology, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA.
Hocine TighiouartInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA; Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA.
Alison G AbrahamDepartment of Epidemiology, John Hopkins Bloomberg School of Public Health, Baltimore, MD.
Gerald J BeckDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
Harold I FeldmanDepartment of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA.
Tom GreeneDepartment of Internal Medicine, University of Utah Health, Salt Lake City, UT.
Vilmundur GudnasonFaculty of Medicine, University of Iceland, Reykjavik, Iceland; Icelandic Heart Association, Kopavogur, Iceland.
Amy B KargerDepartments of Laboratory Medicine and Pathology, University of Minnesota; Department of Medicine, Hennepin County Medical Center, Minneapolis, MN.
John H EckfeldtDepartments of Laboratory Medicine and Pathology, University of Minnesota; Department of Medicine, Hennepin County Medical Center, Minneapolis, MN.
Bertram L KasiskeUniversity of Minnesota; Department of Medicine, Hennepin County Medical Center, Minneapolis, MN.
Michael MauerMedicine, University of Minnesota; Department of Medicine, Hennepin County Medical Center, Minneapolis, MN.
Gerjan NavisFaculty of Medical Sciences, University Medical Center Groningen, Groningen, The Netherlands.
Emilio D PoggioDepartment of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Peter RossingSteno Diabetes Center Copenhagen and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Michael G ShlipakKidney Health Research Collaborative, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA.
Andrew S LeveyDivision of Nephrology, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA.
CKD-EPI GFR Collaborators
Northwestern Medicine · USTufts University · USCleveland Clinic · USUniversity Medical Center Groningen · NLUniversity of Minnesota · USHennepin County Medical Center · USJohns Hopkins University · USTufts Medical Center · USUniversity of California, San Francisco · USUniversity of Copenhagen · DKUniversity of Iceland · ISUniversity of Minnesota System · USUniversity of Pennsylvania · USUniversity of Utah · US
Funding
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2MTransform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MQAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7MNorthwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MSPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5MScientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1MClinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0MMichigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9MTranslational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI JAIME ELIZABETH HART · 1985 to 2026
$44.6MNational Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6MZIPRASIDONE (GEODON) AUGMENTATION IN SEROTONIN REUPTAKE INHIBITOR-RESISTANT OBM01RR000071 · NCRR · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI KOLEVZON, ALEXANDER · 1985 to 2009
$41.5MNCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001105NCATS NIH HHS UL1 TR001420NCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR002319NCATS NIH HHS UL1 TR002494NCATS NIH HHS UL1 TR002548NCATS NIH HHS UL1 TR002556NCATS NIH HHS UL1 TR003096NCATS NIH HHS UL1 TR003098NCRR NIH HHS M01 RR000071NCRR NIH HHS M01 RR000400NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1 RR025777NCRR NIH HHS UL1 RR029879NCRR NIH HHS UL1 RR029887NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146333NIA NIH HHS P30 AG024824NIA NIH HHS P60 AG008808NIDDK NIH HHS K01 DK092353NIDDK NIH HHS K24 DK002651NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK036836NIDDK NIH HHS R01 DK051975NIDDK NIH HHS R01 DK082447NIDDK NIH HHS R01 DK097020NIDDK NIH HHS R01 DK125252NIDDK NIH HHS R01 DK139225NIDDK NIH HHS R03 DK094484NIDDK NIH HHS R21 DK130018NIDDK NIH HHS R34 DK097808NIDDK NIH HHS U01 DK035073NIDDK NIH HHS U01 DK045388NIDDK NIH HHS U01 DK053869NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U01 DK066013NIDDK NIH HHS U24 DK060990NIDDK NIH HHS UC4 DK101108NIGMS NIH HHS P30 GM103337
Abstract
RATIONALE AND
objectiveGlomerular filtration rate (GFR) estimation based on creatinine and cystatin C (eGFR STUDY
designStudy of diagnostic test accuracy. SETTING AND
participantsDevelopment in a pooled population of 7 studies with 5,017 participants with and without chronic kidney disease. External validation in a pooled population of 7 other studies with 2,245 participants. TESTS COMPARED: Panel eGFR using B2M and BTP in addition to cystatin C (3-marker panel) or creatinine and cystatin C (4-marker panel) with and without age and sex or race. OUTCOMES: GFR measured as the urinary clearance of iothalamate, plasma clearance of iohexol, or plasma clearance of [
resultsMean measured GFRs were 58.1 and 83.2 mL/min/1.73 m LIMITATIONS: No representation of participants with severe comorbid illness and from geographic areas outside of North America and Europe.
conclusionsThe 4-marker panel eGFR is as accurate as eGFR
Indexed as
Black or African AmericanGlomerular Filtration RateWhite PeopleAdolescentAdultAgedAged, 80 and overbeta 2-MicroglobulinBlack PeopleCase-Control StudiesChromium RadioisotopesCreatinineCystatin CEdetic AcidFemaleHumansbeta 2-MicroglobulinChromium-51Chromium RadioisotopesCreatinineCystatin CEdetic AcidIntramolecular OxidoreductasesIohexolIothalamic AcidLipocalinsprostaglandin R2 D-isomeraseAfrican AmericanbiasBlack racecreatininecystatin Cestimating equationsfiltration markerGFR estimationGlomerular filtration rate (GFR)kidney disease diagnosislaboratory testingracerace-based medicinerenal functionβ(2)-microglobulin (B2M)β-trace protein (BTP)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.